Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.